MTOR and cancer: Several well-designed clinical trials have compared the MMF and AZA in HTx, highlighting the superiority of the first in terms of cellular rejection and survival.12, 13 According to the literature, it is possible that switching to or adding a mTOR-based immunosuppressive therapy to a patient’s regimen may be beneficial in presence of malignancy.11